sunitinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 2544 557795-19-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sunitinib
  • sunitinib malate
  • sutent
  • SU-011248
  • SU-010398
  • PHA-290940AD
An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.
  • Molecular weight: 398.48
  • Formula: C22H27FN4O2
  • CLOGP: 3
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 77.23
  • ALOGS: -4.11
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 25 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.34 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 54.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
July 19, 2006 EMA
Jan. 26, 2006 FDA CPPI CV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 1046.22 17.09 665 27823 90635 46566939
Palmar-plantar erythrodysaesthesia syndrome 712.83 17.09 314 28174 20137 46637437
Neoplasm progression 597.67 17.09 302 28186 26381 46631193
Renal cell carcinoma 484.46 17.09 149 28339 3389 46654185
Metastatic renal cell carcinoma 450.67 17.09 107 28381 856 46656718
Stomatitis 429.63 17.09 346 28142 67951 46589623
Death 398.67 17.09 723 27765 334825 46322749
Dysgeusia 368.19 17.09 256 28232 40235 46617339
Gastrointestinal stromal tumour 368.03 17.09 94 28394 1046 46656528
Oral pain 363.46 17.09 212 28276 24585 46632989
Yellow skin 330.14 17.09 98 28390 1966 46655608
Hypothyroidism 325.05 17.09 215 28273 31123 46626451
Diarrhoea 308.46 17.09 889 27599 558713 46098861
Renal cancer 292.76 17.09 99 28389 3069 46654505
Thrombocytopenia 260.46 17.09 352 28136 126229 46531345
Hair colour changes 260.33 17.09 79 28409 1713 46655861
Drug ineffective 256.11 17.09 52 28436 677786 45979788
Hypertension 208.29 17.09 404 28084 195952 46461622
Fatigue 203.62 17.09 819 27669 607878 46049696
Decreased appetite 198.51 17.09 393 28095 193443 46464131
Platelet count decreased 196.28 17.09 272 28216 99752 46557822
Renal cancer metastatic 174.10 17.09 41 28447 315 46657259
Mucosal inflammation 139.36 17.09 144 28344 38832 46618742
Rheumatoid arthritis 132.28 17.09 3 28485 240212 46417362
Asthenia 108.36 17.09 425 28063 310650 46346924
Ageusia 100.56 17.09 71 28417 11401 46646173
Vomiting 99.38 17.09 540 27948 452254 46205320
Nausea 95.08 17.09 729 27759 686725 45970849
Drug hypersensitivity 90.98 17.09 19 28469 243806 46413768
Blood pressure increased 89.89 17.09 222 28266 126444 46531130
Blister 86.84 17.09 121 28367 44510 46613064
Dehydration 83.55 17.09 250 28238 159290 46498284
Epistaxis 81.35 17.09 143 28345 64162 46593412
Oral discomfort 81.22 17.09 54 28434 7864 46649710
Dry skin 78.01 17.09 110 28378 40906 46616668
Dyspepsia 77.39 17.09 145 28343 68327 46589247
Second primary malignancy 72.65 17.09 47 28441 6537 46651037
Skin discolouration 70.24 17.09 93 28395 32587 46624987
Pancreatic neuroendocrine tumour 64.19 17.09 18 28470 292 46657282
Hyperkeratosis 63.27 17.09 39 28449 4986 46652588
Blood thyroid stimulating hormone increased 62.56 17.09 41 28447 5828 46651746
Skin exfoliation 62.13 17.09 88 28400 32850 46624724
Glossodynia 59.13 17.09 101 28387 44272 46613302
Pleural effusion 57.33 17.09 144 28344 82808 46574766
Neoplasm malignant 53.80 17.09 69 28419 23430 46634144
Tongue discomfort 51.42 17.09 24 28464 1753 46655821
Arthralgia 46.08 17.09 96 28392 364507 46293067
Ascites 45.78 17.09 81 28407 36503 46621071
Bone marrow failure 45.55 17.09 72 28416 29597 46627977
Malignant neoplasm progression 44.10 17.09 112 28376 64814 46592760
Dry mouth 41.82 17.09 99 28389 54827 46602747
Osteonecrosis of jaw 40.28 17.09 74 28414 34328 46623246
Sinusitis 37.67 17.09 16 28472 129752 46527822
Urticaria 36.76 17.09 13 28475 117879 46539695
Psoriasis 36.68 17.09 3 28485 78601 46578973
Gingival pain 36.33 17.09 30 28458 6073 46651501
Soft tissue sarcoma 36.01 17.09 9 28479 91 46657483
Drug interaction 35.53 17.09 43 28445 203051 46454523
General physical health deterioration 35.23 17.09 152 28336 115617 46541957
Treatment failure 35.19 17.09 7 28481 93080 46564494
Arthropathy 35.04 17.09 5 28483 84695 46572879
White blood cell count decreased 34.65 17.09 148 28340 112083 46545491
Asthma 34.36 17.09 7 28481 91535 46566039
Jaundice 33.70 17.09 62 28426 28783 46628791
Flatulence 32.40 17.09 61 28427 28817 46628757
Hypersensitivity 31.78 17.09 27 28461 150294 46507280
Tumour haemorrhage 31.58 17.09 16 28472 1399 46656175
Plantar erythema 31.45 17.09 10 28478 254 46657320
Injection site pain 31.43 17.09 13 28475 107139 46550435
Pneumonia 30.68 17.09 122 28366 376198 46281376
Thyroid disorder 30.09 17.09 37 28451 12039 46645535
Metastases to liver 29.33 17.09 47 28441 19538 46638036
Neutropenia 29.31 17.09 168 28320 143036 46514538
Intentional overdose 28.91 17.09 3 28485 64941 46592633
Fall 28.55 17.09 104 28384 328993 46328581
Gingival bleeding 27.94 17.09 35 28453 11604 46645970
Bronchitis 27.79 17.09 15 28473 105964 46551610
Renal cell carcinoma stage IV 27.52 17.09 6 28482 31 46657543
Eating disorder 27.40 17.09 39 28449 14615 46642959
Face oedema 27.37 17.09 45 28443 19108 46638466
Hypogeusia 26.91 17.09 13 28475 1026 46656548
Pancytopenia 26.88 17.09 113 28375 84945 46572629
Blood lactate dehydrogenase increased 26.43 17.09 46 28442 20454 46637120
Anxiety 26.38 17.09 44 28444 181913 46475661
Off label use 25.64 17.09 132 28356 379709 46277865
Proteinuria 25.17 17.09 40 28448 16513 46641061
Condition aggravated 25.02 17.09 72 28416 244980 46412594
Joint swelling 24.22 17.09 40 28448 166033 46491541
Musculoskeletal stiffness 24.09 17.09 15 28473 97978 46559596
Thyroiditis 23.88 17.09 14 28474 1634 46655940
Chromaturia 23.81 17.09 37 28451 14982 46642592
Suicide attempt 23.35 17.09 3 28485 55033 46602541
Chest discomfort 23.34 17.09 13 28475 90256 46567318
Hyperaesthesia 22.76 17.09 26 28462 7830 46649744
Wheezing 22.44 17.09 3 28485 53383 46604191
Disseminated intravascular coagulation 22.39 17.09 41 28447 18964 46638610
Generalised oedema 22.17 17.09 35 28453 14364 46643210
Dyspnoea 22.01 17.09 205 28283 515343 46142231
Skin toxicity 21.83 17.09 18 28470 3636 46653938
Weight decreased 21.66 17.09 210 28278 210639 46446935
Eyelid oedema 21.51 17.09 29 28459 10328 46647246
Taste disorder 21.50 17.09 22 28466 5856 46651718
Oral mucosal blistering 21.14 17.09 20 28468 4840 46652734
Nephrotic syndrome 20.93 17.09 20 28468 4901 46652673
Eyelash discolouration 20.83 17.09 5 28483 42 46657532
Periorbital oedema 20.54 17.09 20 28468 5015 46652559
Infection 19.64 17.09 32 28456 133560 46524014
Thyroid function test abnormal 19.53 17.09 16 28472 3202 46654372
Tongue disorder 19.45 17.09 23 28465 7187 46650387
Glossitis 19.28 17.09 15 28473 2788 46654786
Hepatic infection bacterial 19.21 17.09 3 28485 0 46657574
Nephritic syndrome 18.63 17.09 6 28482 159 46657415
Mobility decreased 18.34 17.09 7 28481 60587 46596987
Metastases to central nervous system 18.29 17.09 28 28460 11193 46646381
Incorrect dose administered 18.13 17.09 3 28485 45547 46612027
Suicidal ideation 17.94 17.09 6 28482 56376 46601198
Tongue blistering 17.55 17.09 11 28477 1447 46656127
Pancreatic neuroendocrine tumour metastatic 17.44 17.09 4 28484 27 46657547
Feeding disorder 17.41 17.09 26 28462 10168 46647406
Depression 17.33 17.09 50 28438 170054 46487520

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 2191.96 14.45 1417 44558 78457 29828046
Neoplasm progression 1209.77 14.45 578 45397 17445 29889058
Palmar-plantar erythrodysaesthesia syndrome 1184.65 14.45 537 45438 14333 29892170
Renal cell carcinoma 1059.04 14.45 380 45595 5386 29901117
Metastatic renal cell carcinoma 778.58 14.45 245 45730 2247 29904256
Renal cancer 729.49 14.45 263 45712 3777 29902726
Dysgeusia 644.96 14.45 427 45548 24374 29882129
Death 628.49 14.45 1558 44417 355725 29550778
Gastrointestinal stromal tumour 452.43 14.45 139 45836 1167 29905336
Stomatitis 424.66 14.45 394 45581 36885 29869618
Yellow skin 414.65 14.45 146 45829 1947 29904556
Diarrhoea 410.13 14.45 1280 44695 332823 29573680
Oral pain 368.45 14.45 211 45764 9258 29897245
Osteonecrosis of jaw 358.84 14.45 267 45708 18351 29888152
Fatigue 344.75 14.45 1175 44800 319498 29587005
Hair colour changes 336.30 14.45 116 45859 1449 29905054
Hypothyroidism 327.98 14.45 232 45743 14731 29891772
Hypertension 286.46 14.45 597 45378 120757 29785746
Ageusia 271.61 14.45 170 45805 8783 29897720
Decreased appetite 269.71 14.45 662 45313 149248 29757255
Glossodynia 253.51 14.45 117 45858 3244 29903259
Drug ineffective 214.73 14.45 129 45846 340258 29566245
Renal cancer metastatic 212.64 14.45 64 45911 497 29906006
Neoplasm malignant 173.73 14.45 173 45802 17641 29888862
Dry skin 155.56 14.45 182 45793 22272 29884231
Mucosal inflammation 150.82 14.45 209 45766 30285 29876218
Platelet count decreased 149.11 14.45 428 45547 105701 29800802
Dyspepsia 135.44 14.45 198 45777 30131 29876372
Completed suicide 134.39 14.45 4 45971 99488 29807015
Asthenia 133.65 14.45 681 45294 220609 29685894
Nausea 118.80 14.45 820 45155 296137 29610366
Thrombocytopenia 114.13 14.45 464 45511 136580 29769923
Blood pressure increased 112.70 14.45 302 45673 71626 29834877
Drug interaction 111.61 14.45 86 45889 199482 29707021
Second primary malignancy 100.25 14.45 81 45894 6275 29900228
Blister 99.61 14.45 140 45835 20543 29885960
Drug abuse 98.90 14.45 7 45968 82065 29824438
Blood thyroid stimulating hormone increased 88.53 14.45 55 45920 2801 29903702
Skin discolouration 88.37 14.45 115 45860 15679 29890824
Off label use 85.44 14.45 158 45817 249132 29657371
Skin exfoliation 83.43 14.45 137 45838 23035 29883468
Febrile neutropenia 74.94 14.45 35 45940 106658 29799845
Oral discomfort 73.66 14.45 47 45928 2509 29903994
Epistaxis 68.83 14.45 208 45767 52773 29853730
Pleural effusion 67.35 14.45 258 45717 73808 29832695
Hyperkeratosis 66.54 14.45 49 45926 3308 29903195
Acute kidney injury 66.50 14.45 208 45767 273634 29632869
Overdose 65.13 14.45 24 45951 84313 29822190
Exposed bone in jaw 61.03 14.45 37 45938 1803 29904700
Malignant neoplasm progression 60.22 14.45 245 45730 72042 29834461
Malignant urinary tract neoplasm 59.65 14.45 12 45963 8 29906495
Vomiting 58.64 14.45 554 45421 219264 29687239
Gingival pain 58.63 14.45 38 45937 2084 29904419
Plasma cell myeloma 57.89 14.45 7 45968 53455 29853048
Tongue discomfort 57.84 14.45 22 45953 369 29906134
Hypotension 57.06 14.45 141 45834 200424 29706079
Fall 55.62 14.45 123 45852 181749 29724754
Cardiopulmonary failure 53.69 14.45 46 45929 3865 29902638
Intentional overdose 51.55 14.45 3 45972 41478 29865025
Pneumonia 51.53 14.45 302 45673 334004 29572499
Psoriasis 47.44 14.45 5 45970 42501 29864002
Aortic dissection 44.73 14.45 34 45941 2408 29904095
Suicidal ideation 43.71 14.45 3 45972 36111 29870392
Proteinuria 43.36 14.45 84 45891 16061 29890442
Aggression 42.08 14.45 4 45971 36903 29869600
Dry mouth 42.01 14.45 102 45873 22748 29883755
Renal cell carcinoma stage IV 41.70 14.45 11 45964 49 29906454
Hypogeusia 41.66 14.45 22 45953 820 29905683
Thyroid function test abnormal 41.14 14.45 20 45955 624 29905879
Tachycardia 40.83 14.45 32 45943 73707 29832796
Pancreatic neuroendocrine tumour 40.67 14.45 15 45960 230 29906273
Skin fissures 40.34 14.45 37 45938 3402 29903101
Tongue blistering 39.80 14.45 15 45960 245 29906258
Oxygen saturation decreased 39.69 14.45 9 45966 43431 29863072
Drug hypersensitivity 38.87 14.45 29 45946 68490 29838013
Rhabdomyolysis 38.60 14.45 25 45950 63555 29842948
Asthma 38.52 14.45 5 45970 36169 29870334
Anxiety 38.32 14.45 49 45926 89822 29816681
Urticaria 38.18 14.45 18 45957 54588 29851915
Dehydration 37.79 14.45 321 45654 123218 29783285
Oral mucosal blistering 37.68 14.45 27 45948 1746 29904757
Atrial fibrillation 37.39 14.45 68 45907 108056 29798447
Weight decreased 37.03 14.45 374 45601 150547 29755956
Suicide attempt 36.92 14.45 6 45969 36691 29869812
Bone marrow failure 36.85 14.45 115 45860 29670 29876833
Metastases to liver 36.82 14.45 66 45909 11899 29894604
Wrong technique in product usage process 36.54 14.45 3 45972 31152 29875351
Cardio-respiratory arrest 35.52 14.45 22 45953 57284 29849219
Impaired healing 35.37 14.45 72 45903 14268 29892235
Therapeutic product effect incomplete 35.25 14.45 5 45970 33829 29872674
Abdominal discomfort 34.92 14.45 158 45817 48633 29857870
Metastases to lung 34.43 14.45 51 45924 7844 29898659
Taste disorder 34.25 14.45 34 45941 3449 29903054
Pain in extremity 34.02 14.45 287 45688 109934 29796569
Coronary artery disease 33.82 14.45 17 45958 49695 29856808
Thyroid disorder 33.40 14.45 30 45945 2684 29903819
Cardiac arrest 33.36 14.45 57 45918 92793 29813710
Ascites 33.33 14.45 126 45849 35795 29870708
Agitation 33.18 14.45 21 45954 54052 29852451
Drug reaction with eosinophilia and systemic symptoms 32.71 14.45 3 45972 28485 29878018
Intentional product use issue 32.40 14.45 8 45967 36432 29870071
Anal abscess 31.66 14.45 39 45936 5030 29901473
White blood cell count decreased 31.65 14.45 229 45746 83718 29822785
Renal cancer stage IV 31.40 14.45 7 45968 12 29906491
Hyperhidrosis 31.35 14.45 34 45941 67056 29839447
Myxoedema 31.04 14.45 7 45968 13 29906490
Tremor 30.18 14.45 43 45932 75320 29831183
Periorbital oedema 30.03 14.45 31 45944 3295 29903208
Skin disorder 29.48 14.45 59 45916 11549 29894954
Hospitalisation 28.90 14.45 16 45959 44303 29862200
Product dose omission issue 28.76 14.45 61 45914 91570 29814933
Gastrointestinal toxicity 28.35 14.45 24 45951 1984 29904519
Intentional product misuse 28.24 14.45 9 45966 34658 29871845
Nephrotic syndrome 27.92 14.45 43 45932 6842 29899661
Tumour compression 27.80 14.45 9 45966 91 29906412
Mouth ulceration 27.04 14.45 54 45921 10555 29895948
Abdominal pain 26.74 14.45 322 45653 135332 29771171
Tumour rupture 26.67 14.45 10 45965 161 29906342
Clear cell renal cell carcinoma 26.53 14.45 17 45958 914 29905589
Acute respiratory failure 26.51 14.45 4 45971 25846 29880657
Hyperaesthesia 26.47 14.45 30 45945 3543 29902960
Pain in jaw 26.46 14.45 58 45917 12098 29894405
Inappropriate schedule of product administration 26.40 14.45 14 45961 39714 29866789
Tumour necrosis 26.39 14.45 18 45957 1075 29905428
Pancreatic neuroendocrine tumour metastatic 26.28 14.45 10 45965 168 29906335
Glossitis 25.55 14.45 18 45957 1133 29905370
Flatulence 25.26 14.45 73 45902 18056 29888447
Hypoxia 24.96 14.45 22 45953 47832 29858671
Jaw fistula 24.81 14.45 7 45968 42 29906461
Constipation 24.02 14.45 272 45703 112634 29793869
Treatment noncompliance 23.53 14.45 5 45970 25248 29881255
Gastrooesophageal reflux disease 23.48 14.45 105 45870 32150 29874353
Delirium 23.29 14.45 17 45958 40614 29865889
Respiratory arrest 23.12 14.45 8 45967 29250 29877253
Chronic obstructive pulmonary disease 23.11 14.45 22 45953 46104 29860399
Septic shock 22.88 14.45 39 45936 63568 29842935
Hypersensitivity 22.46 14.45 30 45945 53998 29852505
Disseminated intravascular coagulation 22.43 14.45 80 45895 22091 29884412
General physical health deterioration 22.27 14.45 243 45732 99701 29806802
Metastases to bone 22.07 14.45 47 45928 9611 29896892
Condition aggravated 21.96 14.45 123 45852 137743 29768760
Sinusitis 21.79 14.45 12 45963 33333 29873170
Anaphylactic reaction 21.52 14.45 8 45967 27974 29878529
Depression 20.94 14.45 70 45905 90367 29816136
Hallucination 20.63 14.45 27 45948 49032 29857471
Gingival bleeding 20.57 14.45 36 45939 6368 29900135
Wheezing 20.41 14.45 11 45964 30927 29875576
Bronchitis 20.39 14.45 18 45957 39107 29867396
Skin toxicity 20.29 14.45 25 45950 3224 29903279
Jaundice 20.18 14.45 101 45874 32385 29874118
Tumour haemorrhage 20.06 14.45 22 45953 2506 29903997
Medication error 19.86 14.45 4 45971 20968 29885535
Blood creatinine increased 19.82 14.45 221 45754 91154 29815349
Anal ulcer 19.79 14.45 12 45963 585 29905918
Unresponsive to stimuli 19.58 14.45 8 45967 26411 29880092
Hypertensive crisis 19.48 14.45 41 45934 8316 29898187
Fluid overload 19.48 14.45 3 45972 19089 29887414
Performance status decreased 19.36 14.45 27 45948 3930 29902573
Agranulocytosis 19.15 14.45 5 45970 21937 29884566
Ejection fraction decreased 19.14 14.45 59 45916 15116 29891387
Product quality issue 19.04 14.45 3 45972 18771 29887732
Dyskinesia 19.01 14.45 5 45970 21829 29884674
Haemoptysis 18.87 14.45 96 45879 30982 29875521
Adverse drug reaction 18.86 14.45 6 45969 23139 29883364
Appetite disorder 18.70 14.45 18 45957 1758 29904745
Bradycardia 18.63 14.45 46 45929 65480 29841023
Angular cheilitis 18.54 14.45 7 45968 115 29906388
Metastases to central nervous system 18.47 14.45 37 45938 7247 29899256
Restlessness 18.17 14.45 6 45969 22593 29883910
Respiratory failure 18.16 14.45 86 45889 100556 29805947
Treatment failure 18.01 14.45 16 45959 34663 29871840
Acute myeloid leukaemia 17.98 14.45 3 45972 18003 29888500
Neoplasm recurrence 17.94 14.45 18 45957 1849 29904654
Seizure 17.85 14.45 84 45891 98391 29808112
Upper respiratory tract infection 17.79 14.45 10 45965 27466 29879037
Eating disorder 17.70 14.45 35 45940 6792 29899711
Dental fistula 17.60 14.45 7 45968 133 29906370
Anaemia 17.44 14.45 430 45545 207562 29698941
Unevaluable event 17.32 14.45 14 45961 31771 29874732
Pneumatosis intestinalis 17.29 14.45 21 45954 2669 29903834
Pulmonary hypertension 17.27 14.45 4 45971 19032 29887471
Injection site pain 16.96 14.45 13 45962 30297 29876206
Musculoskeletal stiffness 16.96 14.45 18 45957 35863 29870640
Myelodysplastic syndrome 16.93 14.45 4 45971 18774 29887729
Cholecystitis 16.80 14.45 42 45933 9537 29896966
Gingivitis 16.62 14.45 22 45953 3048 29903455
Scrotal inflammation 16.44 14.45 3 45972 0 29906503
Connective tissue neoplasm 16.44 14.45 3 45972 0 29906503
Drug withdrawal syndrome 16.39 14.45 5 45970 19804 29886699
Drug level increased 16.37 14.45 4 45971 18350 29888153
Pericardial effusion 16.28 14.45 70 45905 21074 29885429
Face oedema 16.13 14.45 46 45929 11288 29895215
Disturbance in attention 15.92 14.45 7 45968 22122 29884381
Dysarthria 15.92 14.45 14 45961 30476 29876027
Lacrimation increased 15.86 14.45 34 45941 6982 29899521
Sedation 15.76 14.45 3 45972 16370 29890133
Skin ulcer 15.76 14.45 64 45911 18785 29887718
Neoplasm of thymus 15.71 14.45 4 45971 15 29906488
International normalised ratio increased 15.63 14.45 31 45944 47708 29858795
Gingival swelling 15.61 14.45 14 45961 1250 29905253
Rash maculo-papular 15.41 14.45 10 45965 25408 29881095
Penile exfoliation 15.32 14.45 4 45971 17 29906486
Osteonecrosis 15.29 14.45 57 45918 16078 29890425
Hepatic cirrhosis 15.26 14.45 3 45972 15996 29890507
Cancer pain 15.22 14.45 19 45956 2483 29904020
Stress 15.20 14.45 6 45969 20229 29886274
Leukocytosis 15.16 14.45 7 45968 21495 29885008
Sepsis 14.97 14.45 148 45827 146247 29760256
Blood lactate dehydrogenase increased 14.94 14.45 67 45908 20534 29885969
Psoriatic arthropathy 14.94 14.45 3 45972 15758 29890745
Incorrect dose administered 14.86 14.45 16 45959 31670 29874833
Anorectal discomfort 14.74 14.45 16 45959 1801 29904702
Pneumonia aspiration 14.68 14.45 22 45953 37758 29868745
Carcinoid tumour 14.62 14.45 6 45969 124 29906379
Myocardial infarction 14.58 14.45 123 45852 125502 29781001
Staphylococcal infection 14.47 14.45 15 45960 30209 29876294

Pharmacologic Action:

SourceCodeDescription
ATC L01EX01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
MeSH PA D020533 Angiogenesis Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006131 Growth Inhibitors
MeSH PA D006133 Growth Substances
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:48422 angiostatic agents
CHEBI has role CHEBI:50846 biomodulator
CHEBI has role CHEBI:62434 alk inhibitor
CHEBI has role CHEBI:63726 neuroprotective agents
CHEBI has role CHEBI:65207 vegfr inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Gastrointestinal stromal tumor indication 420120006 DOID:9253
Renal cell carcinoma indication 702391001 DOID:4450
Pancreatic Neuroendocrine Tumor indication
Acute hemorrhage contraindication 8573003
Hyperkalemia contraindication 14140009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Torsades de pointes contraindication 31722008
Hyperthyroidism contraindication 34486009 DOID:7998
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Bradycardia contraindication 48867003
Hepatic failure contraindication 59927004
Hemoptysis contraindication 66857006
Hypermagnesemia contraindication 66978005
Pancreatitis contraindication 75694006 DOID:4989
Heart failure contraindication 84114007 DOID:6000
Left heart failure contraindication 85232009
Prolonged QT interval contraindication 111975006
Seizure disorder contraindication 128613002
Hypomagnesemia contraindication 190855004
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Thromboembolic disorder contraindication 371039008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Surgical procedure contraindication 387713003
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Hypertensive urgency contraindication 443482000
Posterior reversible encephalopathy syndrome contraindication 450886002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.52 acidic
pKa2 11.68 acidic
pKa3 12.32 acidic
pKa4 9.32 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 12.5MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY
EQ 25MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY
EQ 37.5MG BASE SUTENT CPPI CV N021938 March 31, 2009 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY
EQ 50MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR IC50 8.80 IUPHAR DRUG LABEL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 10.12 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Kd 9.70 CHEMBL CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase INHIBITOR Kd 9.66 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 9.68 CHEMBL CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase INHIBITOR Kd 8.70 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Ki 7.77 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR IC50 7.23 SCIENTIFIC LITERATURE DRUG LABEL
Platelet-derived growth factor receptor alpha Kinase INHIBITOR IC50 6.96 SCIENTIFIC LITERATURE DRUG LABEL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.31 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Kinase IC50 4.89 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.62 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 5.68 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 6.54 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 6.01 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 5.89 CHEMBL
Insulin receptor Kinase AGONIST Kd 6.74 CHEMBL
Calcium/calmodulin-dependent protein kinase type IV Kinase Kd 6.05 CHEMBL
Serine/threonine-protein kinase BRSK1 Kinase Kd 5.46 CHEMBL
Fibroblast growth factor receptor 4 Kinase Kd 5.68 CHEMBL
SRSF protein kinase 1 Kinase Kd 6.60 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2 Kinase Kd 6.17 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 5.42 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 5.92 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 7.89 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 5.77 CHEMBL
Serine/threonine-protein kinase PAK 3 Kinase Kd 7.80 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit beta Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 6.39 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 5.62 CHEMBL
MAP/microtubule affinity-regulating kinase 3 Kinase Kd 6.39 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase Kd 7.02 CHEMBL
Serine/threonine-protein kinase NIM1 Kinase Kd 6.07 CHEMBL
Cyclin-G-associated kinase Kinase Kd 7.70 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 6.70 CHEMBL
Mitogen-activated protein kinase kinase kinase 15 Kinase Kd 5.89 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 6.70 CHEMBL
Aurora kinase A Kinase Kd 5.77 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 7.34 CHEMBL
Tyrosine-protein kinase JAK1 Kinase Kd 8.05 CHEMBL
Casein kinase I isoform delta Kinase Kd 7.82 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 7.89 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 7.39 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 7.51 CHEMBL
Serine/threonine-protein kinase pim-3 Kinase Kd 5.62 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 6.46 CHEMBL
Wee1-like protein kinase Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 5.68 CHEMBL
Interferon-induced, double-stranded RNA-activated protein kinase Kinase Kd 6.17 CHEMBL
NUAK family SNF1-like kinase 1 Kinase Kd 7.32 CHEMBL
Serine/threonine-protein kinase BRSK2 Kinase Kd 5.96 CHEMBL
U4/U6 small nuclear ribonucleoprotein Prp4 Unclassified Kd 6.41 CHEMBL
Serine/threonine-protein kinase D1 Kinase Kd 6.51 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 7.02 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 6.92 CHEMBL
Serine/threonine-protein kinase ICK Kinase Kd 6.33 CHEMBL
Serine/threonine-protein kinase Nek7 Kinase Kd 5.39 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.80 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 6.22 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1 Kinase Kd 5.41 CHEMBL
MAP/microtubule affinity-regulating kinase 4 Kinase Kd 5.44 CHEMBL
Serine/threonine-protein kinase OSR1 Kinase Kd 6.28 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.57 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 6.55 CHEMBL
Serine/threonine-protein kinase Sgk3 Kinase Kd 6.66 CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 7.03 CHEMBL
Dual specificity protein kinase CLK2 Kinase Kd 7.70 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 6.74 CHEMBL
Myosin light chain kinase family member 4 Kinase Kd 7.82 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.28 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 7.26 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 7.66 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 7.20 CHEMBL
Serine/threonine-protein kinase tousled-like 2 Kinase Kd 6.48 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.72 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 5.96 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 6.60 CHEMBL
Serine/threonine-protein kinase 17B Kinase Kd 6.96 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase Kd 6.36 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 6.72 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 7.96 CHEMBL
Serine/threonine-protein kinase MARK2 Kinase Kd 6.51 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.92 CHEMBL
Ribosomal protein S6 kinase alpha-5 Kinase Kd 7.77 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 6.80 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 6.92 CHEMBL
Serine/threonine-protein kinase 38 Kinase Kd 6.39 CHEMBL
Serine/threonine-protein kinase N2 Kinase Kd 5.89 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.30 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 6.05 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 6.06 CHEMBL
Aurora kinase C Kinase Kd 6.66 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 8.23 CHEMBL
Casein kinase I isoform gamma-1 Kinase Kd 6.03 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 7 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 6.28 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 6.28 CHEMBL
Rho-associated protein kinase 1 Kinase Kd 6.34 CHEMBL
Ribosomal protein S6 kinase alpha-3 Kinase Kd 7.26 CHEMBL
Citron Rho-interacting kinase Kinase Kd 5.41 CHEMBL
Myosin-IIIa Kinase Kd 5.51 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.80 CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1 Kinase Kd 6.51 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 6.54 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 7.64 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 5.48 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 7.39 CHEMBL
Serine/threonine-protein kinase 38-like Kinase Kd 6.01 CHEMBL
Serine/threonine-protein kinase DCLK2 Kinase Kd 5.57 CHEMBL
Misshapen-like kinase 1 Kinase Kd 7.54 CHEMBL
Casein kinase I isoform alpha-like Kinase Kd 6.26 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 7.12 CHEMBL
Serine/threonine-protein kinase PAK 6 Kinase Kd 5.62 CHEMBL
Interleukin-1 receptor-associated kinase 4 Kinase Kd 7.18 CHEMBL
Insulin receptor-related protein Kinase Kd 6.37 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 8.26 CHEMBL
Serine/threonine-protein kinase pim-2 Kinase Kd 5.30 CHEMBL
Serine/threonine-protein kinase PAK 7 Kinase Kd 6.19 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 9 CHEMBL
Insulin-like growth factor 1 receptor Kinase Kd 5.59 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 5.89 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.02 CHEMBL
Megakaryocyte-associated tyrosine-protein kinase Kinase Kd 5.11 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 7.60 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 5.82 CHEMBL
Ribosomal protein S6 kinase alpha-4 Kinase Kd 7.02 CHEMBL
Aurora kinase B Kinase Kd 6.42 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 7.25 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 7.54 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 5.24 CHEMBL
Death-associated protein kinase 2 Kinase Kd 6.82 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 5.62 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 6.44 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 7.85 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 7.72 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 5.34 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 1 Kinase Kd 6.38 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 6.29 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 7.25 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G Kinase Kd 6.36 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase Kd 7.72 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 6.30 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.57 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 7.77 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 7.89 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 6.32 CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase Kd 8.26 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 5.66 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Kinase IC50 4.96 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 6.89 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 6.74 CHEMBL
Focal adhesion kinase 1 Kinase Kd 6.36 CHEMBL
Casein kinase II subunit alpha Kinase Kd 7.09 CHEMBL
RAC-beta serine/threonine-protein kinase Kinase Kd 5.57 CHEMBL
NT-3 growth factor receptor Kinase Kd 5.29 CHEMBL
Serine/threonine-protein kinase STK11 Kinase Kd 7.42 CHEMBL
Interleukin-1 receptor-associated kinase 3 Kinase Kd 6.03 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 7.10 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 7.24 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 7.38 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 6 CHEMBL
Serine/threonine-protein kinase MARK1 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 6.47 CHEMBL
Serine/threonine-protein kinase PLK2 Kinase Kd 5.33 CHEMBL
Bone morphogenetic protein receptor type-2 Kinase Kd 6.24 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 7.09 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 7.19 CHEMBL
Serine/threonine-protein kinase LATS2 Kinase Kd 6.34 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit alpha Kinase Kd 6.28 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1B Kinase Kd 5.64 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 6.21 CHEMBL
Serine/threonine-protein kinase PRP4 homolog Kinase Kd 6.41 CHEMBL
SNF-related serine/threonine-protein kinase Kinase Kd 6.19 CHEMBL
Dual serine/threonine and tyrosine protein kinase Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.07 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase IC50 4.92 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 6.68 CHEMBL
Casein kinase I isoform alpha Kinase Kd 7 CHEMBL
Tankyrase-2 Enzyme Kd 5.05 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.48 CHEMBL
Rho-associated protein kinase 2 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase 24 Kinase Kd 7.20 CHEMBL
Casein kinase I isoform gamma-3 Kinase Kd 6.62 CHEMBL
Death-associated protein kinase 1 Kinase Kd 6.92 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-2 Kinase Kd 7.05 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 6.28 CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3 Kinase Kd 5.72 CHEMBL
Hormonally up-regulated neu tumor-associated kinase Kinase Kd 6.30 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 5.54 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 5.92 CHEMBL
Death-associated protein kinase 3 Kinase Kd 7.66 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 5.41 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 6.96 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 6.57 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 6.74 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase Kd 6.70 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 5.70 CHEMBL
Cyclin-dependent kinase 18 Kinase Kd 5.77 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase LATS1 Kinase Kd 6.20 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 7.31 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 6.02 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 6.64 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 7.31 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 5.47 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 5.74 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.77 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 8.05 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta Kinase Kd 7.41 CHEMBL
3-phosphoinositide-dependent protein kinase 1 Kinase Kd 5.46 CHEMBL
Serine/threonine-protein kinase D2 Kinase Kd 6.42 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 6.23 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.82 CHEMBL
Protein delta homolog 1 Unclassified Kd 7 CHEMBL
SRSF protein kinase 2 Kinase Kd 6.72 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 6.96 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 6.15 CHEMBL
Serine/threonine-protein kinase tousled-like 1 Kinase Kd 6.13 CHEMBL
SRSF protein kinase 3 Kinase Kd 7.23 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 6 Kinase Kd 5.28 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 6.77 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 7 CHEMBL
Myosin light chain kinase 3 Kinase Kd 7.64 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 6.43 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha Kinase Kd 5.27 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.66 CHEMBL
Cyclin-dependent-like kinase 5 Kinase Kd 5.16 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 7.46 CHEMBL
Cyclin-dependent kinase 4 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase RIO2 Kinase Kd 7.31 CHEMBL
Ribosomal protein S6 kinase beta-1 Kinase Kd 7.32 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 7.64 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 7.77 CHEMBL
Serine/threonine-protein kinase Chk2 Kinase Kd 8.15 CHEMBL
Casein kinase I isoform gamma-2 Kinase Kd 6.96 CHEMBL
Testis-specific serine/threonine-protein kinase 1 Kinase Kd 5.20 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase Kd 6.38 CHEMBL
Serine/threonine-protein kinase Chk1 Kinase Kd 6.52 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 6.15 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 7.48 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 5.49 CHEMBL
Protein kinase C alpha type Kinase Kd 5.22 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 7.59 CHEMBL
Mitogen-activated protein kinase 7 Kinase Kd 5 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.17 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.51 SCIENTIFIC LITERATURE
Ephrin type-A receptor 7 Kinase Kd 5.62 SCIENTIFIC LITERATURE
Rhodopsin kinase Kinase Kd 6.54 CHEMBL
Myosin-IIIb Kinase Kd 5.35 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.37 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 6.89 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 7.26 CHEMBL
Epidermal growth factor receptor Kinase Kd 6.07 CHEMBL
Protein kinase C theta type Kinase Kd 5.37 CHEMBL
Serine/threonine-protein kinase DCLK1 Kinase Kd 6.43 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 6.26 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 7.64 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 6.96 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 6.80 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 7.06 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 5.89 CHEMBL

External reference:

IDSource
4025079 VUID
N0000175350 NUI
D06402 KEGG_DRUG
341031-54-7 SECONDARY_CAS_RN
4025079 VANDF
4025080 VANDF
C1176021 UMLSCUI
CHEBI:38940 CHEBI
B49 PDB_CHEM_ID
CHEMBL1567 ChEMBL_ID
CHEMBL535 ChEMBL_ID
D000077210 MESH_DESCRIPTOR_UI
8646 INN_ID
DB01268 DRUGBANK_ID
V99T50803M UNII
6456015 PUBCHEM_CID
5713 IUPHAR_LIGAND_ID
357977 RXNORM
20930 MMSL
21012 MMSL
75586 MMSL
d05717 MMSL
011192 NDDF
011193 NDDF
421192001 SNOMEDCT_US
421448007 SNOMEDCT_US
426455008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0550 CAPSULE 12.50 mg ORAL NDA 34 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0770 CAPSULE 25 mg ORAL NDA 34 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0830 CAPSULE 37.50 mg ORAL NDA 34 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0980 CAPSULE 50 mg ORAL NDA 34 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 63539-017 CAPSULE 12.50 mg ORAL NDA 34 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 63539-019 CAPSULE 50 mg ORAL NDA 34 sections